Evidence map›Paper›PMID 36653340›Full record

ArticleCell death & disease2023

HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells.

Yimeng Zhang, Peng Ding, Yuanyong Wang, Changjian Shao, Kai Guo, Hanyi Yang, Yingtong Feng, Jiayi Ning, Minghong Pan, Ping Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. HDAC7 promotes ovarian cancer malignancy via AKT/mTOR signalling pathway.Journal of cellular and molecular medicine · 2024
    Article
  9. Review
  10. Article
  11. HDAC7: a promising target in cancer.Frontiers in oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Yimeng Zhang *Department of Ophthalmology, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.
Peng Ding *Department of Thoracic Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.
Yuanyong Wang *Department of Thoracic Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.ORCID 0000-0002-7753-8736
Changjian ShaoDepartment of Thoracic Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.
Kai GuoDepartment of Thoracic Surgery, Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710068, China.
Hanyi YangDepartment of Ophthalmology, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.
Yingtong FengDepartment of Cardiothoracic Surgery, The Affiliated Huaihai Hospital of Xuzhou Medical University/The 71th Group Army Hospital of PLA, 236 Tongshan Road, Xuzhou, 221004, China.
Jiayi NingDepartment of Ophthalmology, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.
Minghong PanDepartment of Thoracic Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.
Ping WangDepartment of Ophthalmology, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China.
Xiaolong YanDepartment of Thoracic Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China. yanxiaolong@fmmu.edu.cn.ORCID 0000-0003-2419-9707
Zhiqiang MaDepartment of Medical Oncology, Senior Department of Oncology, Chinese PLA General Hospital, The Fifth Medical Center, Beijing, 100853, China. mazhiqiang@301hospital.com.cn.
Jing HanDepartment of Ophthalmology, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China. hanjing.cn@163.com.ORCID 0000-0003-2584-443X
Tang Du Hospital · CNXi'an Medical University · CNChinese PLA General Hospital · CNShaanxi Provincial People's Hospital · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choroidal melanoma (CM) is the most common type of diagnosed uveal melanoma (UM), which is prone to metastasis and exhibits a poor prognosis. The molecular mechanisms underlying CM progression need further elucidation to research effective therapeutic strategies. Histone deacetylase 7 (HDAC7) is very important in regulating cancer progression, but the significance and effect of HDAC7 on CM progression are unclear. In the present study, we found that HDAC7 is overexpressed in CM tissues versus normal tissues. We built HDAC7 overexpressing CM cell lines to study the functions of HDAC7 in CM progression and verified that upregulation of HDAC7 promoted the proliferation and metastasis of CM cells, while pharmacological inhibition of HDAC7 suppressed both the proliferation and metastasis of CM cells. Furthermore, we found that the aforementioned cancer-promoting effect of HDAC7 was mediated by c-Myc. Targeted inhibition of c-Myc inhibited CM progression by interfering with the HDAC7/c-Myc signaling pathway. Our study highlighted the function of targeting the HDAC7/c-Myc signaling pathway to intervene in the pathological process of CM, which provides potential therapeutic strategies for CM treatment.

Indexed as

MelanomaProto-Oncogene Proteins c-mycCell ProliferationHistone DeacetylasesHumansSignal TransductionUveal MelanomaUveal NeoplasmsHDAC7 protein, humanHistone DeacetylasesProto-Oncogene Proteins c-myc

Identifiers

PMID36653340
PMCPMC9849404
OpenAlexW4317382988

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.